Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
- PMID: 25282563
- PMCID: PMC4180007
- DOI: 10.1016/j.jaci.2014.08.005
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Abstract
Background: Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization.
Objective: Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates.
Methods: We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator.
Results: Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups.
Conclusion: The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.
Keywords: Atopic dermatitis; eczema; emollients; prevention; skin barrier.
Crown Copyright © 2014. Published by Elsevier Inc. All rights reserved.
Figures
Comment in
-
Porphylactic emollient use beginning at birth prevents atopic dermatitis.J Pediatr. 2015 Mar;166(3):777-8. doi: 10.1016/j.jpeds.2014.12.045. J Pediatr. 2015. PMID: 25722275 No abstract available.
-
Preventing atopic eczema from birth using emollients.J Allergy Clin Immunol. 2015 Jun;135(6):1663-4. doi: 10.1016/j.jaci.2015.01.051. J Allergy Clin Immunol. 2015. PMID: 26051953 No abstract available.
-
Reply: To PMID 25282563.J Allergy Clin Immunol. 2015 Jun;135(6):1664. doi: 10.1016/j.jaci.2015.01.050. J Allergy Clin Immunol. 2015. PMID: 26051954 No abstract available.
Similar articles
-
Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health Technol Assess. 2024 Jul;28(29):1-116. doi: 10.3310/RHDN9613. Health Technol Assess. 2024. PMID: 39021147 Free PMC article. Clinical Trial.
-
Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.Trials. 2017 Jul 21;18(1):343. doi: 10.1186/s13063-017-2031-3. Trials. 2017. PMID: 28732519 Free PMC article. Clinical Trial.
-
A randomized controlled trial of an emollient with ceramide and filaggrin-associated amino acids for the primary prevention of atopic dermatitis in high-risk infants.J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2087-2094. doi: 10.1111/jdv.15786. Epub 2019 Jul 30. J Eur Acad Dermatol Venereol. 2019. PMID: 31287580 Clinical Trial.
-
A Global Review on the Risk Factors and Management of Early Atopic Dermatitis in Children Ages 0 to 2 Years Old.J Drugs Dermatol. 2019 Oct 1;18(10):1020-1027. J Drugs Dermatol. 2019. PMID: 31584781 Review.
-
Bath emollients for atopic eczema: why use them?Drug Ther Bull. 2007 Oct;45(10):73-5. doi: 10.1136/dtb.2007.09.0015. Drug Ther Bull. 2007. PMID: 17928284 Review.
Cited by
-
Treatment of Atopic Dermatitis in Children.Cureus. 2024 Sep 14;16(9):e69416. doi: 10.7759/cureus.69416. eCollection 2024 Sep. Cureus. 2024. PMID: 39403661 Free PMC article. Review.
-
Biologic and Small Molecule Therapy in Atopic Dermatitis.Biomedicines. 2024 Aug 13;12(8):1841. doi: 10.3390/biomedicines12081841. Biomedicines. 2024. PMID: 39200305 Free PMC article. Review.
-
Evaluation of Childhood Allergy Risk Among Pregnant Women in a Tertiary Care Hospital in Thailand.Cureus. 2024 Jun 27;16(6):e63322. doi: 10.7759/cureus.63322. eCollection 2024 Jun. Cureus. 2024. PMID: 39070479 Free PMC article.
-
Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT.Health Technol Assess. 2024 Jul;28(29):1-116. doi: 10.3310/RHDN9613. Health Technol Assess. 2024. PMID: 39021147 Free PMC article. Clinical Trial.
-
Tape Stripping - Searching for Minimally Invasive Biomarkers in Atopic Dermatitis.Dermatol Pract Concept. 2024 Apr 1;14(2):e2024123. doi: 10.5826/dpc.1402a123. Dermatol Pract Concept. 2024. PMID: 38810072 Free PMC article. Review.
References
-
- Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC phase three. J Allergy Clin Immunol. 2009;124:1251–1258.e23. - PubMed
-
- Williams H., Stewart A., von Mutius E., Cookson W., Anderson H.R. International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947–954.e15. - PubMed
-
- Spergel J.M. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105:99–109. 117. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
